EVM201 program / Enveric Biosci - LARVOL DELTA

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) (Businesswire) - "Enveric Biosciences, Inc...announced that its research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) being held in Vancouver June 4-8, 2023...The first poster...describes the chemical synthesis of Enveric’s EVM201 Series molecules to identify novel prodrugs of psilocin with altered metabolic profiles and reduced pharmacological exposure aimed at reducing the duration of the psychedelic experience. Beginning with 30 unique molecules, representing nine distinct prodrug classes, 15 candidates were selected that released the highest levels of psilocin in vitro....The second poster... The results show how modifications to the chemical structure of MDMA can lead to substantial alteration in binding to different serotonin receptors and transporters, which could alter pharmacological properties."

Preclinical • CNS Disorders • Mood Disorders • Psychiatry

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference (Businesswire) - “Enveric Biosciences…announced the presentation of results from its lead programs at the 6th International Neurology & Brain Disorders Conference (INBC) to be held on October 24-26, 2022, in Orlando, Florida…Enveric’s first poster presentation, related to the EVM201 development program, describes the screening and pharmacological characterization of a portfolio of novel psilocin prodrugs, comprising of nine distinct prodrug classes….Enveric’s second poster presentation, related to the EVM301 development program, describes the discovery and characterization of novel methods and tools to accelerate the future discovery of additional promising neuroactive drug candidates.”

Clinical data • CNS Disorders